SlideShare utilise les cookies pour améliorer les fonctionnalités et les performances, et également pour vous montrer des publicités pertinentes. Si vous continuez à naviguer sur ce site, vous acceptez l’utilisation de cookies. Consultez nos Conditions d’utilisation et notre Politique de confidentialité.
SlideShare utilise les cookies pour améliorer les fonctionnalités et les performances, et également pour vous montrer des publicités pertinentes. Si vous continuez à naviguer sur ce site, vous acceptez l’utilisation de cookies. Consultez notre Politique de confidentialité et nos Conditions d’utilisation pour en savoir plus.
What happens at each study visit?
Interview Examination Blood tests
JUvenile NCL Mycophenolate Phase II Clinical Trial (JUMP)
EF Augustine, HR Adams, JW Mink, A Vierhile, S Defendorf, FJ Marshall
University of Rochester Batten Center, Rochester, New York, email@example.com
Current treatments for Juvenile Neuronal Ceroid
Lipofuscinosis (JNCL; CLN3 disease) help manage
some symptoms, but do not change the overall course
of the disease. New treatments are needed. We are
conducting a phase II trial of mycophenolate mofetil
(CellCept) in children with JNCL.
Goals of the trial
1)To understand whether CellCept is safe when given to
children with JNCL for a short period of time.
1)To look for early signs of whether CellCept affects JNCL
symptoms like seizures, walking, mood, and thinking ability.
1)To test a new way for researchers and physicians to work
together to study rare diseases.
This research is supported by the BDSRA and the FDA Office of
Orphan Products Development grant program (R01 FD003908).
Study contacts: Amy Vierhile, PNP; Sara Defendorf; and Erika
Augustine, MD 585-275-4762,
What happens during the study?
• The study lasts 22 weeks
• Each child receives 8 weeks of placebo and 8 weeks of
CellCept. The placebo is a sugar liquid without active
medication. All children receive active medication at some
point in the study.
• During the study, each child completes 4 visits at the
University of Rochester Batten Center of Excellence and 4
visits with a local doctor, for a total of 8 study visits.
• 30 children will be enrolled into the trial.
• Several children have completed the trial.
• We continue to enroll new children into the study.
Autoimmunity in JNCL
• The immune response is the human body’s toolkit for
• Antibodies are one of the tools in the immune
response toolkit. The antibodies’ job is to attack
• When antibodies mistakenly attack one’s own body
(instead of infections), they are called autoantibodies,
and the immune response is called autoimmunity.
• Blood tests from children and mice with JNCL/CLN3
shows signs of autoimmunity. This autoimmunity may
interfere with certain aspects of brain function. 1, 2
• If the immune response is suppressed in mice with
CLN3 disease, the mice have better motor function for
a longer period of time.3
• Treating children who have JNCL with medications
that suppress the immune system might be one way
to slow the course of the disease, by decreasing the
number of autoantibodies in the blood.
• What is it? A medication that suppresses the immune
response (including autoantibodies)
• How is it given? By mouth twice a day, in liquid form
• What are the current uses approved by the Food and Drug
Prevention of organ transplant rejection in children
• What are the important known side effects? Increased risk
of infection, stomach upset
1.Ramirez-Montealegre D, et al. Autoimmunity to glutamic acid
decarboxylase in the neurodegenerative disorder Batten disease.
Neurology. 2005; 64(4):743-5.
2.Chattopadhyay S, et al. An autoantibody to GAD65 in sera of
patients with juvenile neuronal ceroid lipofuscinoses. Neurology.
3.Seehafer SS, et al., Immunosuppression alters disease severity in
juvenile Batten disease mice. J. Neuroimmunol. 2011; 230: 169-172.
• If CellCept is safe for children with JNCL, then future trials
will be needed to understand how CellCept affects the
disease course when given for a long period of time.
• Participation in ongoing studies of JNCL symptoms helps
researchers design better trials for the future.
Who can participate?
• Males and females
• JNCL confirmed by CLN3 genetic testing*
• Able to walk 10 feet independently (may use a cane, walker, or
person for guidance related to vision loss)
* If genetic testing has not been performed already, this will be
completed during the screening for entry into the trial